COVID-19 Rapid Response: Identifying & developing next-generation COVID-19 therapeutics

Major Funding
$6,325,000.00

Grant Value

2023-24

Fiscal Year

Description

Identify and develop antibody therapeutics for response and preparedness against COVID-19, and expand capacity for rapid development and delivery of antibody therapeutics.

Expected Results

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization

Grant Details
Recipient

AbCellera Biologics Inc.

Operating as: AbCellera

Location

Vancouver, BC V5Y 0A1

Agreement Details

Number: 1002444

Reference: 172-2022-2023-Q4-1002444

Timeline

Start: Nov. 1, 2022

End: March 31, 2024

Program

Industrial Research Assistance Program Contributions to Firms

The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …

Sector

Professional, scientific and technical services (541710)

Your Contribution

Calculate how much you personally contributed to this grant through your taxes.

Calculate My Share
Share This Grant
Back to All Grants